A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 07 Dec 2017 Status changed from recruiting to completed.
- 09 Oct 2017 The study has been completed in Bulgaria(End date: 2017-07-19).
- 03 Oct 2017 The study has been completed in Lithuania (End date: 2017-07-19).